Results 91 to 100 of about 4,744 (194)

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis [PDF]

, 2018
BACKGROUND: Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients and is often the result of reduced activity of the key metabolic enzyme dihydropyrimidine dehydrogenase (DPD), mostly caused by genetic variants in the gene ...
Meulendijks, Didier, Nieboer, Peter, van Schaik, Ron H N, Hamberg, Paul, van Schaik, Ron H. N., Ten Tije, Albert J, Lunenburg, Carin A.T.C., Werkhoven, Erik van; id_orcid, Frederix, Geert W. J., Jeurissen, Frank J. F., Jansen, Rob L.H., Dezentjé, Vincent O, Droogendijk, Helga J, van de Poel, Marlène H W, Creemers, Geert Jan, Droogendijk, Helga J., Mathijssen, Ron H.J.; id_orcid, Beijnen, Jos H, Kienhuis, Emma, Swen, Jesse J., Guchelaar, Henk-Jan, Frederix, Geert W.J., Henricks, Linda M, van de Poel, Marlène H.W., ten Tije, Albert J., Cats, Annemieke, Jeurissen, Frank J.F., Imholz, Alexander L. T., Imholz, Alexander L T, Creemers, Geert-Jan, Schellens, Jan H M, de Man, Femke M., Swen, Jesse J, Mathijssen, Ron H.J., Mandigers, Caroline M.P.W., van Kuilenburg, André B. P., Beijnen, Jos H., Mathijssen, Ron H J, Frederix, Geert W J, Portielje, Johanna E.A., Jansen, Rob L. H., Gelderblom, Hans, Mandigers, Caroline M P W, Dezentjé, Vincent O., Guchelaar, Henk Jan, van Kuilenburg, André B.P., van Schaik, Ron H.N., Imholz, Alexander L.T., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Mandigers, Caroline M. P. W., Koopman, Miriam, Lunenburg, Carin A T C, van Kuilenburg, André B P, Mathijssen, Ron H. J., de Man, Femke M, Lunenburg, Carin A. T. C., Schellens, Jan H. M., Jeurissen, Frank J F, van Werkhoven, Erik, Henricks, Linda M., Baars, Arnold, Werkhoven, Erik van, van de Poel, Marlène H. W., Schellens, Jan H.M., Rosing, Hilde, Portielje, Johanna E A, Jansen, Rob L H, Portielje, Johanna E. A.   +68 more
core   +3 more sources

New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.

, 2020
Several clinical guidelines recommend genetic screening of DPYD, including coverage of the variants c.1905 + 1G>A(DPYD*2A), c.1679T>G(DPYD*13), c.2846A>T, and c.1129-5923C>G, before initiating treatment with fluoropyrimidines.
Robles, Luis, Pachón, Vanessa, Thomas, Fabienne, López-Fernández, Luis A, López-Fernández, Luis, García-Alfonso, Pilar, Salvador-Martín, Sara, Kaczmarczyk, Bartosz, Abarca-Zabalía, Judith, Vaz, Ángeles, García-González, Xandra, Sanjurjo-Sáez, María   +11 more
core   +1 more source

ACKR1/Duffy‐null genotype testing for clozapine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 1977-1990, July 2026.
Abstract Clozapine is licenced for treatment‐resistant schizophrenia and psychosis in Parkinson's disease. In the United Kingdom, there is a mandatory requirement for absolute neutrophil count (ANC) and white blood cell count (WBC) monitoring to safeguard against agranulocytosis.
Stephen Murtough, Oriella Stellakis, Daisy Mills, Blanca Bjourson, Vicky Chaplin, Dharmisha Chauhan, Bev Chipp, Marius Cotic, Jana de Villiers, Olubanké Dzahini, Frances Elmslie, Katie Evans, Shreyans Gandhi, Dyfrig A. Hughes, Huajie Jin, Daniele Panconesi, Anna Skowronska, Sanjay M. Sisodiya, Ed Silva, Vicky Stinton, Sara Stuart‐Smith, Sarah Tarrant, David Taylor, Lauren Varney, James T. R. Walters, Michelle Wood, Jessica Woodley, Cinzia Dello Russo, Munir Pirmohamed, Elvira Bramon   +29 more
wiley   +1 more source

53BP1 regulates the levels of TS and DPYD.

, 2013
(A) The mRNA levels of TS in 53BP1 transfected MDA-MB-231 and MCF-7 cells. (B) The mRNA levels of DPYD in 53BP1 transfected cells. (C) The protein levels of TS and DPYD in 53BP1 transfected cells. (D) The transfection efficiency of siRNA TS was confirmed
Yang Wang (5921), Shi Yan (164233), Xiangnan Kong (308090), Qifeng Yang (88905), Xiaoyan Li (117291), Xiaoli Kong (337303)   +5 more
core   +1 more source

Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene

, 2010
Objectives: Dihydropyrimidine dehydrogenase (DPD) is the initial rate-limiting enzyme in endogenous pyrimidine catabolism and is responsible for the reduction of the pyrimidine analog 5-fluorouracil (5-FU).
Shubbar, Emman, Albertsson, Per, Enerbäck, Charlotta, Enerbäck, Charlotta,, Arkblad, Eva, Skrtic, Stanko, Ofverholm, Anna,, Shubbar, Emman,, Arkblad, Eva,, Albertsson, Per,, Ofverholm, Anna, Skrtic, Stanko,   +11 more
core   +1 more source

The development, implementation, and evaluation of a DPYD testing program in British Columbia

, 2023
A third of patients develop severe or life-threatening toxicities from fluoropyrimidines, a commonly prescribed chemotherapeutic. Fluoropyrimidine toxicity is often due to variation in the gene (DPYD) encoding dihydropyrimidine dehydrogenase (DPD).
Wu, Angela
core   +1 more source

Fluoropyrimidine Toxicities and DPYD Genotyping: A Clinical Case

Cureus
Fluoropyrimidines are metabolized mainly by the enzyme dihydropyrimidine dehydrogenase (DPD). Some variants in the coding gene, DPYD, have already been associated with increased toxicity, and their testing is recommended in patients proposed for treatment with these drugs.
Peixoto, Maurício, Alves, Diana, Lopes, Altina, Queiróz, Luísa, Almeida, Marta   +4 more
openaire   +2 more sources

Accelerating Rotarod phenotyping in Dpyd knockout and wildtype mice (dpyd_ko_rr_long.xlsx)

, 2021
Dataset with phenotypes from Accelerating Rotarod testing in Dpyd knockout mice and wildtype control ...
Brendan Keenan (11377554)
core   +1 more source

Frequency of DPYD Mutation in Patients with Adverse Effects of 5-Fluorouracil Therapy

Medical Journal of Babylon
Background: Fluoropyrimidines are widely used in the treatment of various solid tumors. One-third of cancer patients develop severe treatment-related toxicity.
Bassam Musa Sadik Al-Musawi, Wisam Jasim Muhammed, Adil Adil Naji, Alaa Abdul-Razaak Al-Anbagi   +3 more
doaj   +1 more source

Characterization of a Rare Nonpathogenic Sequence Variant (c.1905C>T) of the Dihydropyrimidine Dehydrogenase Gene ()

The International Journal of Biological Markers, 2017
Background In the era of precision medicine, the suitability of fluoropyrimidine therapies in clinical oncology can be checked by pharmacogenetic investigations of single patients, thus optimizing resources and indicating the appropriate drugs to ...
Raffaele Palmirotta, Domenica Lovero, Erica Silvestris, Claudia Carella, Claudia Felici, Davide Quaresmini, Paola Cafforio, Franco Silvestris   +7 more
doaj   +1 more source